NOVOS Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
Later Stage VC
- Investors
-
24
NOVOS General Information
Description
Provider of healthcare drink supplement enriched with anti-aging and longevity qualities intended to improve mental health and wellness. The company's products include nicotinamide riboside, magnesium, fisetin, and pterostilbene, as well as antioxidants and other functional ingredients that improve DNA repair and reduce DNA damage, allowing consumers to expand their lifespan and improve their health.
Contact Information
Website
www.novoslabs.comCorporate Office
- 100 Park Avenue
- 16th Floor
- New York, NY 10017
- United States
Corporate Office
- 100 Park Avenue
- 16th Floor
- New York, NY 10017
- United States
NOVOS Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 05-Mar-2026 | Completed | Generating Revenue | |||
| 1. Seed Round | 01-Oct-2021 | Completed | Generating Revenue |
NOVOS Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-2 | ||||||||
| Seed-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NOVOS Patents
NOVOS Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026064455-A1 | Senolytic compositions and uses thereof | Pending | 20-Sep-2024 | ||
| EP-4518832-A1 | Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan | Pending | 06-May-2022 | ||
| EP-4518832-A4 | Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan | Pending | 06-May-2022 | ||
| US-20260248840-A1 | Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan | Pending | 06-May-2022 | ||
| WO-2023215454-A1 | Chondroitin- and collagen peptide-based methods for slowing down aging and extending lifespan | Inactive | 06-May-2022 | A61K38/39 |
NOVOS Signals
NOVOS Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Unilever Ventures | Corporate Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Arkitekt Ventures | Venture Capital | Minority | ||
| Asia Venture Group | Venture Capital | Minority |
NOVOS FAQs
-
When was NOVOS founded?
NOVOS was founded in 2018.
-
Where is NOVOS headquartered?
NOVOS is headquartered in New York, NY.
-
What is the size of NOVOS?
NOVOS has 32 total employees.
-
What industry is NOVOS in?
NOVOS’s primary industry is Pharmaceuticals.
-
Is NOVOS a private or public company?
NOVOS is a Private company.
-
What is NOVOS’s current revenue?
The current revenue for NOVOS is .
-
How much funding has NOVOS raised over time?
NOVOS has raised $3.62M.
-
Who are NOVOS’s investors?
Unilever Ventures, , , Arkitekt Ventures, and Asia Venture Group are 5 of 24 investors who have invested in NOVOS.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process